0001209191-15-040135.txt : 20150507
0001209191-15-040135.hdr.sgml : 20150507
20150507175847
ACCESSION NUMBER: 0001209191-15-040135
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150501
FILED AS OF DATE: 20150507
DATE AS OF CHANGE: 20150507
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001338042
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 202960116
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 500-7867
MAIL ADDRESS:
STREET 1: ONE MAIN STREET
STREET 2: SUITE 800
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc
DATE OF NAME CHANGE: 20050906
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Carter Martha J.
CENTRAL INDEX KEY: 0001213040
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34921
FILM NUMBER: 15843345
MAIL ADDRESS:
STREET 1: C/O AEGERION PHARMACEUTICALS, INC.
STREET 2: 89 HEADQUARTERS PLAZA, SUITE 1212
CITY: MORRISTOWN
STATE: NJ
ZIP: 07960
FORMER NAME:
FORMER CONFORMED NAME: CARTER MARTHA J
DATE OF NAME CHANGE: 20030106
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2015-05-01
0
0001338042
Aegerion Pharmaceuticals, Inc.
AEGR
0001213040
Carter Martha J.
C/O AEGERION PHARMACEUTICALS, INC.
ONE MAIN STREET, SUITE 800
CAMBRIDGE
MA
02142
0
1
0
0
See Remarks
Stock Option (right to buy)
23.61
2015-05-01
4
A
0
13000
0.00
A
2025-05-01
Common Stock
13000
13000
D
Restricted Stock Units
2015-05-01
4
A
0
3000
0.00
A
Common Stock
3000
3000
D
The stock option award has an exercise price equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant.
25% of the shares of common stock underlying this stock option award will vest on May 1, 2016, with the remaining 75% of the shares of common stock underlying this stock option award vesting thereafter in equal monthly installments through May 1, 2019, subject to the Reporting Person's continued employment with the Issuer.
Each restricted stock unit represents a contingent right to receive one share of common stock.
The restricted stock units will vest in three annual installments, with 33.34% of the units vesting on May 1, 2016, 33.33% of the units vesting on May 1, 2017, and 33.33% of the units vesting on May 1, 2018, subject to the Reporting Person's continued employment with the Issuer.
Chief Regulatory Officer and Senior Vice President
/s/ Anne Marie Cook, attorney-in-fact
2015-05-07